

Growth Hormones

Phone: 800-728-7947 Fax back to: 866-880-4532

	Prescriber Name:	
Patient Name:	Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable)	:
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.		
Q1. Please indicate location of administration. Home Long Term Care (LTC) facility Physician office (drug from office stock - buy and bill) Physician office (drug from pharmacy with a prescription)		
Q2. Is this being prescribed by an endocrinologist or a ped	liatric endocrinologist?	
☐ Yes ☐ No		
Q3. What is the patient's age? ☐ Greater than 18 years (go to question 4) ☐ Less than or equal to 18 years (go to question 11)		
Q4. Adults: For what diagnosis is this drug being prescribe Growth hormone deficiency (GHD) Other	d (pick one)?	
Q5. Does the patient have irreversible hypothalamic-pituita surgery, or trauma)?	ary disease (etiologies may include	radiation therapy,



Growth Hormones

Phone: 800-728-7947 Fax back to: 866-880-4532

Patient Name:		Prescriber Name: Supervising Physician:
		Supervising r nysician.
Yes [No	
Q6. Does the patient have low	IGF-1 level (e.g. less than 2	.5 percentile or less than -2 standard deviations)?
☐ Yes [□ No	
Q7. Does the patient have a negative response to GH stimulation testing (peak GH < 5 μg/L) based on insulin tolerance test? (Acceptable alternative stimulation tests: growth hormone releasing hormone (GHRH) + arginine (ARG), glucagon or ARG)		
☐ Yes [□ No	
Q8. Has the patient previously been treated for Childhood-Onset Growth Hormone Deficiency (COGHD) with GH therapy?		
☐ Yes [□ No	
Q9. Does the patient have pan-hypopituitarism (greater than or equal to 3 pituitary hormone deficiencies)?		
☐ Yes [□ No	
Q10. Does the patient have low IGF-1 level (e.g. less than 2.5 percentile or less than -2 standard deviations)?		
Q11. Pediatrics: For what diagr		cribed (pick ana)?
Growth hormone deficiency		cribed (pick one):
☐ Turner syndrome (TS)		
☐ Small for gestational age (S	SGA)	
Growth failure in children w	rith chronic renal insufficienc	cy
☐ Prader-Willi syndrome (PW	(S)	
☐ Noonan syndrome (and other FDA-approved dwarfing syndromes)		
Other		
Q12. Please provide ICD code(s) for diagnosis.		
Q13. Pediatrics: Is this request	for a patient being newly sta	arted on GH therapy for GHD?
☐ Yes [□ No	
Q14. Pediatric GHD new start: (e.g. > 2 standard deviations (S	· · · · · · · · · · · · · · · · · · ·	ed short stature defined as height less than 3rd percentile and gender)?
☐ Yes [□ No	



Growth Hormones

Phone: 800-728-7947 Fax back to: 866-880-4532

Patient Name:	Prescriber Name: Supervising Physician:	
Q15. Pediatric GHD new start: Does the patient have grow (e.g. < 2 SD below mean for age)?	vth failure defined as height velocity less than 3rd percentile	
Q16. Pediatric GHD new start: Does the patient have less severe short stature combined with moderate growth failure (e.g. growth velocity < 15th percentile or less than 1 SD)? ☐ Yes ☐ No		
Q17. Pediatric GHD new start: Does the patient have a documented GHD as evidenced by low IGF-1 and/or IGFBP-3 levels (e.g. values > 2 SD below the mean for IFG-1 or IFGB-3)? Yes No		
Q18. Pediatric GHD new start: Does the patient have diminished serum growth hormone level based on TWO of the following stimulation tests: arginine, glucagon, or clonidine? ☐ Yes ☐ No		
Q19. Pediatric GHD continuation: Does the patient have a	documented epiphyseal closure?	
Q20. Pediatric GHD continuation: Does the patient have a growth rate velocity of greater than or equal to 2.5 cm/year?		
Q21. Pediatrics: Is this request for a patient being newly started on GH therapy for TS?		
Q22. Pediatric TS new start: Has the patient been diagnos	sed with TS using chromosome analysis?	
Q23. Pediatric TS new start:Does the patient have short s	tature?	
Q24. Pediatric TS continuation: Does the patient have a b	one age of greater than or equal to 14 years of age?	
Q25. Pediatrics: Is this request for a patient being newly s	tarted on GH therapy for SGA?	
Q26. Pediatric SGA new start: Has the patient's height remained less than 3rd percentile (e.g. > 2 SDS below the		



Growth Hormones

Phone: 800-728-7947 Fax back to: 866-880-4532

Patient Name:	Prescriber Name: Supervising Physician:	
mean for age and sex) at 2 years of age? ☐ Yes ☐ No		
Q27. Pediatric SGA continuation: Does the patient have a cm/year?	growth rate velocity of greater than or equal to 2.5	
Yes No		
Q28. Pediatrics: Is this request for a patient being newly s insufficiency?	tarted on GH therapy for growth failure due to chronic renal	
Yes No		
	way the failt was provided at first at how for the property in the state of the provided at the state of the sta	
Q29. Pediatric chronic renal insufficiency new start: Has g uremic growth failure have been adequately stabilized and	·	
☐ Yes ☐ No		
Q30. Pediatric chronic renal insufficiency continuation: Do	es the nationt have a documented eniphyseal closure?	
Yes No	es the patient have a documented epiphyseal closure:	
Q31. Pediatric chronic renal insufficiency continuation: Ha	s the patient had a renal transplant?	
☐ Yes ☐ No		
Q32. Pediatrics: Is this request for a patient being newly s	tarted on GH therapy for PWS?	
☐ Yes ☐ No		
Q33. Pediatric PWS new start: Has the patient been diagnosed with PWS using chromosome analysis and/or appropriate genetic evaluation?		
☐ Yes ☐ No		
Q34. Pediatric PWS new start: Does the patient have grow	wth failure?	
☐ Yes ☐ No		
Q35. Pediatric PWS new start: Is the patient's weight greater than 225% of ideal body weight (e.g. severely obese)?		
☐ Yes ☐ No		
Q36. Pediatric PWS new start: Does the patient have resp polysomnography)?	piratory impairment or sleep apnea (evaluated by	
☐ Yes ☐ No		
Q37. Pediatric PWS continuation: Does the patient have a documented epiphyseal closure?		



Growth Hormones

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:		Prescriber Name: Supervising Phys	
Yes] No		
Q38. Pediatric PWS continuation	n: Has the patient had new	onset respiratory	impairment or sleep apnea?
☐ Yes ☐] No		
Q39. Pediatrics: Is this request for approved dwarfing syndromes)?		arted on GH thera	py for Noonan syndrome (or other FDA-
☐ Yes ☐] No		
Q40. Pediatric dwarfing syndrom	ne new start: Does the pati	ent have short sta	ture?
☐ Yes ☐] No		
Q41. Pediatric dwarfing syndrom	ne continuation: Does the p	patient have a doc	umented epiphyseal closure?
☐ Yes ☐] No		
Q42. Additional Comments			
Prescriber Sig	gnature		Date

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical director at 1-888-316-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Growth Hormones

Phone: 800-728-7947

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Fax back to: 866-880-4532

	Prescriber Name:
Patient Name:	Supervising Physician:

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document